From its home near Cambridge, EMBL’s European Bioinformatics Institute has become essential infrastructure for modern life science. Built on open data, expert curation and international collaboration, EMBL-EBI now faces rising demand, rapid advances in artificial intelligence and the need to keep trusted biological information available for everyone, wherever discovery happens.
EMBL’s European Bioinformatics Institute, widely known as EMBL-EBI, was created in 1994 at the Wellcome Genome Campus in Hinxton, near Cambridge. Its origins reach back further, to the EMBL Nucleotide Sequence Data Library, one of the early efforts to organise and share the rapidly growing outputs of molecular biology. That heritage matters, because EMBL-EBI was never designed as a conventional research organisation alone. It was built as shared scientific infrastructure: a place where biological data could be stored, checked, connected and made usable by researchers across borders. As genomics moved from specialist activity to mainstream science, the institute’s role expanded quickly. The sequencing of the human genome, advances in proteomics, structural biology, metabolomics and functional genomics all created new forms of evidence. EMBL-EBI helped make those outputs discoverable and reusable. Its public mission, as part of the European Molecular Biology Laboratory, has remained consistent: to help scientists realise the potential of big data in biology, while keeping access open wherever possible.
Today, EMBL-EBI maintains one of the world’s most comprehensive ranges of molecular data resources and analysis tools. Its services support life science research in universities, hospitals, biotechnology companies, pharmaceutical businesses, public health agencies and conservation programmes. Resources such as the GWAS Catalog, the International Genome Sample Resource and AlphaFold Database illustrate the breadth of its contribution, from human genetic variation to predicted protein structures. Tools including UniProt ID Mapping, Annotare and annotation platforms help researchers connect identifiers, submit functional genomics data and interpret complex records. This work can look technical from the outside, but its business value is tangible. An independent analysis by Frontier Economics found that EMBL-EBI data resources deliver multibillion-pound benefits each year, including major productivity gains for users in the public and private sectors. The same report indicated that the benefits are far higher than the costs of maintaining the resources. For managers, investors and policy makers, that finding is important: open biodata is not simply a scientific good, but enabling infrastructure for innovation.
The industry surrounding bioinformatics is now under pressure from several directions. Data volumes continue to rise as sequencing becomes cheaper, imaging becomes more detailed and environmental sampling reaches previously uncharted biological systems. At the same time, artificial intelligence is changing expectations about what biological databases should do. High quality, well described data is essential for training reliable AI tools, yet the usefulness of those tools still depends on accuracy, provenance and context. EMBL-EBI’s response is grounded in data stewardship. Its open science policy makes databases, code and software freely available whenever possible, while its licensing approach seeks machine-readable terms, including CC0 where appropriate. The institute also recognises that automation must be handled carefully. Curators are increasingly using text mining, machine learning, large language models and other AI methods to scale annotation, but these approaches are subject to evaluation and quality control. In an era when organisations are tempted to prioritise speed, EMBL-EBI’s emphasis on trust is a competitive strength.
Long-term resilience is another defining challenge. Biological data has a long life: a sequence, protein model or disease association may remain useful for decades, especially when linked to new evidence. EMBL-EBI addresses this through resource life cycle management, staffing continuity, infrastructure planning, backup systems and delivery through international partners. Its role in ELIXIR also supports coordination of biological data provision across Europe. The organisation’s workforce reflects that international outlook. More than three quarters of staff have joined from outside the UK, and EMBL-EBI continues to recruit globally, supported by its status as part of an intergovernmental organisation rather than a body formally tied to the European Union. This matters because the skills required to run modern biodata services are scarce and multidisciplinary, spanning biology, software engineering, curation, cloud infrastructure, user support and training. EMBL-EBI’s training work further extends its impact, helping researchers and industry teams use data responsibly. In practical terms, its current approach combines openness with discipline: making information accessible, while investing in the systems and people needed to keep it reliable.
EMBL-EBI’s story shows how patient public investment can create lasting value for science and business. Its future influence will depend on openness, resilient infrastructure, trusted curation and international collaboration worldwide. As biological data expands, organisations will need partners who combine technology with scientific judgement consistently. For business leaders, the lesson is clear: shared foundations can accelerate competitive innovation responsibly globally. By sustaining open biodata, EMBL-EBI helps discoveries move faster, further and with greater confidence worldwide.
